|Bid||29.33 x 800|
|Ask||29.82 x 900|
|Day's Range||28.53 - 29.84|
|52 Week Range||24.06 - 32.81|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.57|
Adaptive Biotechnologies Corp. shares rocketed 96% in their first ten minutes of trade Thursday, after the company priced its initial public offering above its price range. The life-sciences research and clinical diagnostics company that says data from the immune system is the key to diagnosing and treating diseases, priced its IPO at $20 a share, bove the pricing range it gave early Wednesday of between $18 and $19, which was already a boost from the company's original pricing range of between $15 and $17 a share. Adaptive sold 15 million shares to raise $300 million, and shares are trading on the Nasdaq under the symbol ADPT. The stock of BridgeBio Pharma Inc. , meanwhile, soared more than 70% in its trading debut. That company also priced its IPO above the price range, selling 20.5 million shares priced at $17 each to raise $348.6 million. The price range was $14 to $16. The stock is trading on Nasdaq, under the ticker symbol "BBIO."
BridgeBio Pharma (NASDAQ: BBIO ) made its public debut Thursday morning, opening at $30.61 after being priced at $17 per share. JPMorgan, Goldman Sachs, Jefferies, SVB Leerink, KKR, Piper Jaffray, Mizuho ...
BridgeBio Pharma Inc. priced its initial public offering late Wednesday at $17 a share, above its price range of $14 to $16. The biotech sold 20.5 million shares to raise $348.5 million. The stock will start trading later Thursday on Nasdaq, under the ticker symbol "BBIO."
PALO ALTO, Calif., June 26, 2019 -- BridgeBio Pharma, Inc. (“BridgeBio”) today announced the pricing of its initial public offering of 20,500,000 shares of its common stock at.
BridgeBio Pharma LLC increased the number of shares it will be offering in its initial public offering by 33% to 20 million from 15 million, according to a filing with the Securities and Exchange Commission on Wednesday. The number of shares to be outstanding after the IPO increased to 120 million shares from 115 million. The expected pricing of the IPO remains at $14 to $16 a share, so the drug discovery company will now be looking to raise up $320 million and will be valued at about $1.92 billion, before the lead underwriters exercise any options to buy up to 3 million additional shares. The company said its stock has been approved to list on the Nasdaq under the ticker symbol "BBIO." The company increased its share offering at a time the Renaissance IPO ETF has gained 1.8% over the past three months and the S&P 500 has tacked on 3.5%.